DOCSLIB.ORG

Southampton Joint Formulary Cumulative Update

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Southampton Joint Formulary Cumulative Update SOUTHAMPTON JOINT FORMULARY CUMULATIVE UPDATE This document is a cumulative list summarising changes to the Southampton Joint Formulary. To check the current status of a medicine please refer to www.southamptonformulary.nhs.uk Date Drug and formulation Colour BNF Comments Action status section 3/2/2020 Medroxyprogesterone Green 7.3.2.2 Sayana Press brand added Amend acetate [Depo- as an alternative option Provera/Sayana Press] (useful for women who wish to self-administer – see primary care guidance here). 3/2/2020 Clonidine 50 micrograms Red 2.5.2 Restricted– only for short- Add in 5ml oral solution term, off label use in sedation/opioid withdrawal in high care paediatrics in accordance with UHS protocol; oral solution for use only when tablet formulation not suitable 3/2/2020 Olaparib capsules/tablets Red 8.1.5 Olaparib for maintenance Amend treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer in adults with a BRCA1 or BRCA2 mutation. For use within the Cancer Drugs Fund. Replaces NICE TA381. Note: only the ‘tablets’ formulation are covered by this TA and TA598 (capsules are due to be discontinued) 3/2/2020 Lusutrombopag tablets Red 9.1.4 NICE TA617: Add [Mulpleo] Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure. 3/2/2020 Cladribine capsules Red 10.2 NICE TA616: Cladribine for Amend [Mavenclad] treating relapsing–remitting multiple sclerosis. Replaces NICE TA493 3/2/2020 Cannabidiol 100mg per Red 4.8.1 Registered specialist only. Add ml oral solution NICE TAs614 and 615: [Epidyolex] Cannabidiol with clobazam for treating seizures associated with Lennox– Date Drug and formulation Colour BNF Comments Action status section Gastaut syndrome and Dravet syndrome 3/2/2020 Palbociclib capsules Red 8.1.5 NICE TA619: Palbociclib with Amend [Ibrance] fulvestrant for treating HR- positive, HER2-negative, advanced breast cancer. For use within the Cancer Drugs Fund. Blueteq registration required. 3/2/2020 Cycloserine capsules Red 5.1.9 Specialist microbiology/TB Add service recommendation only. (For use in accordance with WHO Guidelines for multi drug-resistant tuberculosis). 3/2/2020 Clofazimine capsules Red 5.1.9 Unlicensed. Add Specialist microbiology/TB service recommendation only. (For use in accordance with WHO Guidelines for multi drug-resistant tuberculosis). 3/2/2020 Diltiazem prolonged- Blue 2.6.2 Cost effective alternative Add release capsules brand for use in primary [Zemtard XL] care. 3/2/2020 Diltiazem prolonged- Green 2.6.2 Amended from blue to Amend release capsules [Viazem green. XL] This will now be the brand of choice at UHS. 3/2/2020 Diltiazem prolonged- Green 2.6.2 Discontinued by Remove release capsules manufacturers [Slozem] 3/2/2020 Zanamivir inj [Dectova] Red 5.3.4 For treatment of complicated Add and potentially life- threatening influenza A or B virus infection in accordance with official guidance. 3/2/2020 Fluticasone/umeclidinium Green 3.2 Amended from amber to Amend /vilanterol DPI [Trelegy green. Ellipta] 3/2/2020 Beclometasone/formotero Green 3.2 Amended from amber to Amend l/glycopyrronium MDI green. [Trimbow] 3/2/2020 Buprenorphine oral Amber 4.10.3 Not initiated in UHS. Add lyophilisate tablets Note: this brand is not [Espranor] interchangeable with other buprenorphine products. Date Drug and formulation Colour BNF Comments Action status section 18/12/19 Histidine, tryptophan, Red 9.2.2.1 Restricted – for specialist Add ketoglutarate perfusion cardiac surgery use only. Off solution [Custodiol] label use for administration into renal arteries as renal protection during open thoracoabdominal aortic aneurysm repair surgery. Solution is classed as a medical device – CE marked. 18/12/19 Rucaparib tablets Red 8.1.5 NICE TA611: Rucaparib for Add [Rubraca] maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer 18/12/19 Neratinib tablets Red 8.1.5 NICE TA612: Neratinib for Add [Nerlynx] extended adjuvant treatment of hormone receptor-positive, HER2- positive early stage breast cancer after adjuvant trastuzumab 18/12/19 Sodium zirconium Red 9.2.1.1 NICE TA599: for treating Add cyclosilicate powder for hyperkalaemia oral suspension [Lokelma] 18/12/19 Cyclizine Green 4.6 RAG status updated. Amend tablet/injection Red Remains as green for oral, intramuscular or subcutaneous administration. Changed to red for intravenous administration. Due to safety concerns, intravenous use of cyclizine at UHS is restricted to short- term (i.e. single dose) only. 18/12/19 Oxetacaine & antacid oral Amber 12.3.1 Reclassified from ‘red’ to Amend suspension ‘amber’ as per DPC recommendations Dec 2019. Unlicensed product included in Drug Tariff specials list. For use in cancer care for oral mucositis and oesophageal lesions causing painful swallowing (see monograph here). 18/12/19 Ibrutinib tablets Red 8.1.5 Tablets introduced in various Amend [Imbruvica] strengths to replace capsules formulation (discontinued) Date Drug and formulation Colour BNF Comments Action status section 18/12/19 Cefazolin injection Red 5.1.2.1 For MSSA bacteraemia in Add patients with mild penicillin allergy who are not suitable for treatment with flucloxacillin. SPC and PIL available on MHRA website. 18/12/19 Fluticasone propionate Amber 12.2.1 For chronic rhinosinusitis Add nasal drops [Flixonase with nasal polyps as second Nasule Drops] line option if control with glucocorticoid nasal sprays is insufficient. DPC recommend indication and intended duration of use should be communicated to primary care. 18/12/19 Melatonin modified Amber 4.1.1 Slenyto formulation added Amend release tablets as an option in accordance [Circadin/Slenyto] with DPC recommendations Aug 2019. Restricted use - CAMHS initiation/supervision only for use in children with sleep disorders in accordance with DPC Shared Care guidance (currently under review). Tablets may be crushed but this will result in loss of modified-release properties. Note: use of Circadin in this setting will be off label, but is established practice. Current patients established on this formulation may continue. 21/11/19 Safinamide tablets Amber 4.9.1 Status amended to Amber Amend [Xadago] as per Shared Care Guidelines for Parkinson’s. Black triangle status removed. 21/11/19 Guanfacine Prolonged Amber 4.4 Added to formulary as per Add release tablets [Intuniv] CAMHS Shared Care guidelines for ADHD. 21/11/19 Insulin degludec 100 Green 6.1.1.2 Switched from amber to Amend units per ml injection green as per DPC Jun 19. [Tresiba] 21/11/19 Lumacaftor and ivacaftor Red 3.7 Added as per NHS England Add Tablets/granules access agreement. Negative [Orkambi] NICE TA398 removed for clarity. Date Drug and formulation Colour BNF Comments Action status section 21/11/19 Tezacaftor and ivacaftor Red 3.7 Added as per NHS England Add [Symkevi] access agreement for CF patients. 21/11/19 Ivacaftor tablets Red 3.7 Added as per NHS England Amend [Kalydeco] access agreement for CF patients. 21/11/19 Tranexamic acid 5% Red 2.11 Unlicensed special added for Add mouthwash use in post oral surgery bleeding. 21/11/19 Isavuconazole capsules Red 5.2.1 Added to formulary as Add or injection [Cresemba] already in use and commissioned by NHSE. 21/11/19 Rivaroxaban tablets Green 2.8.2 NICEIncluded TA607 on :Bluteq. Rivaro xaban Amend [Xarelto] for preventing atherothrombotic events in people with coronary or peripheral artery disease 21/11/19 Pentosan polyfusate Red 7.4.3 NICE TA610: Pentosan Amend sodium capsules polysulfate sodium for treating bladder pain syndrome. 21/11/19 Lanadelumab 300mg Red 3.4.3 NICE TA606: Lanadelumab Add subcutaneous injection for preventing recurrent attacks of hereditary angioedema. 21/11/19 Levonorgestrel IUS Amber 7.3.2.3 Second entry for use in Add [Kyleena] obstetrics off-label for heavy menstrual bleeding where Mirena/Levosert devices are too large 21/11/19 Lubiprostone capsules NA 1.6.7 Removed from formulary as Remove [Amitiza] has been discontinued in UK 21/11/19 Pembrolizumab injection Red 8.1.5 NICE TA477 removed and Amend replaced by TA600. 23/10/19 Pembrolizumab inj Red 8.1.5 NICE TA600: for untreated Amend metastatic squamous non small-cell lung cancer (with carboplatin and paclitaxel). For use within the Cancer Drugs Fund. 23/10/19 Botulinum neurotoxin Red 1.2 NICE TA605: Xeomin Amend type A [Xeomin] (botulinum neurotoxin type A) for treating chronic sialorrhoea. Date Drug and formulation Colour BNF Comments Action status section 23/10/19 Bictegravir/emtricitabine/ Red 5.3.1 Treatment for HIV-1 in Add enofovir/alafenamide adults in line with criteria tablets [Biktarvy] stipulated in NHS England Clinical Commissioning Policy (170131P). Specialist use only. 23/10/19 Pitolisant tablets [Wakix] Red 4.1 For specialist sleep clinic use Add in patients aged ≥18 years, only when conventional stimulants have failed/not tolerated, and sodium oxybate is not suitable/not tolerated. 23/10/19 Flecainide oral solution Amber 2.3.2 Unlicensed special. Add 25mg in 5ml For use in children unable to swallow tablets. 23/10/19 Heparin Sodium Flush 50 Amber 2.8.1 Restricted use in primary Amend units in 5ml care. GPs to prescribe only for children for administration by specialist paediatric community nurses. 28/08/19 Bedaquiline tablets Red 5.1.9 For multidrug-resistant and Add [Sirturo] extensively drug-resistant tuberculosis in line with criteria stipulated in NHS England Clinical Commissioning Policy (170132P). Specialist use only. All patients must be registered on
Load more

Recommended publications
  • Globus Hystericus — an Overview
    Bangladesh Journal of Psychiatry. June, 1995, 7, 1, 32 GLOBUS HYSTERICUS — AN OVERVIEW Anwarul Haider1, M S I Mullick2, Md Shakhawat Islam3 Introduction Globus hystericus, Globus pharynges, Functional no abnormality7. The condition may be due to dysphagia, Globus syndrome are synonymous1. spasm of upper oesophageal sphincter. Many of It is a pscyhogenic disorder of alimentary tract the patients have reflux oesophagities. extremely common, the cause is poorly Oesphageal reflux due to abnormality in cardia understood, indeed may be relieved by may produce vague upper end symptoms, swallowing food or drink, occurs in tense anxious antacids reported to help if this is the case589. individuals23. Globus hystericus should not be diagnosed until an organic lesion especially a malignancy has been excluded10, all other causes of dysphagia Natural History : has to be excluded carefully. The patient often Persistent feeling or sensation of a lump in the admits to psychological stress or cancer phobia11. throat, usually in mid line, localised just above An attempt should be made to offer insight in the the supra steranl notch around the level of cricoid nature of the problem, a detail history, careful cartilage, is the commonest complain, mainly examination with x-ray if appropriate will help to occurs in anxious, middle aged, menopausal reassure a certain number of patients. A history ladies34. There is interference with swallowing but of friends or relatives with throat disease requires no true dysphagia for solid & liquid and the sympathetic probing12. symptoms often noticeable in empty swallowing One also has to remember that even most of saliva, are often diagnosed as globus if on neurotic patient, however on rare occasions is examination nothing found5.
    [Show full text]
  • Tavalisse™ (Fostamatinib) (Oral) Document Number: IC-0361 Last Review Date: 02/02/2021 Date of Origin: 06/01/2018 Dates Reviewed: 06/2018, 02/2019, 02/2020, 02/2021
    Tavalisse™ (fostamatinib) (Oral) Document Number: IC-0361 Last Review Date: 02/02/2021 Date of Origin: 06/01/2018 Dates Reviewed: 06/2018, 02/2019, 02/2020, 02/2021 I. Length of Authorization Coverage is provided for six months and may be renewed. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: 100 mg tablets – 2 tablets per day 150 mg tablets – 2 tablets per day B. Max Units (per dose and over time) [HCPCS Unit]: 300 mg daily III. Initial Approval Criteria 1,2 Coverage is provided in the following conditions: Patient is at least 18 years of age; AND Universal Criteria 1 Patient is not receiving a thrombopoietin receptor agonist or mimetic (e.g., romiplostim, eltrombopag, lusutrombopag, avatrombopag, etc.); AND Laboratory values are current (i.e., drawn within the previous 28 days); AND Fostamatinib is not being used to attempt to normalize platelet count; AND Patient will avoid concomitant therapy with any of the following: o Coadministration with strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ketoconazole, etc.), or if therapy is unavoidable, the patient will be monitored closely for adverse reaction and/or dose modifications will be implemented; AND o Coadministration with strong CYP3A inducers (e.g., rifampin, carbamazepine, St. John’s Wort, etc.); AND Chronic Immune Thrombocytopenia (ITP) † 1-5 Patient has had persistent/chronic ITP for at least 3 months; AND Proprietary & Confidential © 2021 Magellan Health, Inc. Patient has previously failed any of the following treatments for ITP: Patient has failed previous therapy with corticosteroids (i.e., patient had no response to at least a 3-month trial or is corticosteroid-dependent); OR Patient has failed previous therapy with immunoglobulins; OR Patient has had a splenectomy; OR Patient has failed previous therapy with a thrombopoietin receptor agonist; AND The patient is at increased risk for bleeding as indicated by platelet count of less than 30 × 109/L (30,000/mm³) † FDA Approved Indication(s) IV.
    [Show full text]
  • Blood Modifier Agents Policy #: Rx.01.208
    Pharmacy Policy Bulletin Title: Blood Modifier Agents Policy #: Rx.01.208 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract. Some medications may be subject to precertification, age, quantity, or formulary restrictions (ie limits on non-preferred drugs). Individual member benefits must be verified. This pharmacy policy document describes the status of pharmaceutical information and/or technology at the time the document was developed. Since that time, new information relating to drug efficacy, interactions, contraindications, dosage, administration routes, safety, or FDA approval may have changed. This Pharmacy Policy will be regularly updated as scientific and medical literature becomes available. This information may include new FDA-approved indications, withdrawals, or other FDA alerts. This type of information is relevant not only when considering whether this policy should be updated, but also when applying it to current requests for coverage. Members are advised to use participating pharmacies in order to receive the highest level of benefits. Intent: The intent of this policy is to communicate the medical necessity criteria for eltrombopag olamine (Promacta®), fostamatinib disodium (Tavalisse™), avatrombopag (Doptelet®), lusutrombopag (Mulpleta®) as provided under the member's prescription drug benefit. Description: Idiopathic thrombocytopenia purpura (ITP): ITP is an immune disorder in which the blood doesn't clot normally. ITP can cause excessive bruising and bleeding and can be characterized as an unusually low level of platelets, or thrombocytes, in the blood results in ITP. Thrombocytopenia in patients with hepatitis C: Thrombocytopenia can occur in patients with chronic hepatitis C virus (HCV) infection.
    [Show full text]
  • Multiple Technology Appraisal Avatrombopag and Lusutrombopag
    Multiple Technology Appraisal Avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520] Committee papers © National Institute for Health and Care Excellence 2019. All rights reserved. See Notice of Rights. The content in this publication is owned by multiple parties and may not be re-used without the permission of the relevant copyright owner. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE MULTIPLE TECHNOLOGY APPRAISAL Avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520] Contents: 1 Pre-meeting briefing 2 Assessment Report prepared by Kleijnen Systematic Reviews 3 Consultee and commentator comments on the Assessment Report from: • Shionogi 4 Addendum to the Assessment Report from Kleijnen Systematic Reviews 5 Company submission(s) from: • Dova • Shionogi 6 Clarification questions from AG: • Questions to Shionogi • Clarification responses from Shionogi • Questions to Dova • Clarification responses from Dova 7 Professional group, patient group and NHS organisation submissions from: • British Association for the Study of the Liver (BASL) The Royal College of Physicians supported the BASL submission • British Society of Gastroenterology (BSG) 8 Expert personal statements from: • Vanessa Hebditch – patient expert, nominated by the British Liver Trust • Dr Vickie McDonald – clinical expert, nominated by British Society for Haematology • Dr Debbie Shawcross – clinical expert, nominated by Shionogi © National Institute for Health and Care Excellence 2019. All rights reserved. See Notice of Rights. The content in this publication is owned by multiple parties and may not be re-used without the permission of the relevant copyright owner. MTA: avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure Pre-meeting briefing © NICE 2019.
    [Show full text]
  • Advances in Hepatology and Robley Rex VAMC NAFLD/NASH
    Luis S. Marsano, MD, FAASLD, FACG, AGAF, FASGE Professor of Medicine, Director of Hepatology University of Louisville Advances in Hepatology and Robley Rex VAMC NAFLD/NASH Coagulation in Cirrhosis Topics Hepatocellular Carcinoma Miscellaneous Definitions of NAFLD, NAFL and NASH Nonalcoholic fatty liver disease (NAFLD) a. Evidence of hepatic steatosis by imaging or histology b. Lack of secondary causes of hepatic fat accumulation Non-alcoholic steato-hepatitis (NASH) Nonalcoholic fatty liver (NAFL) ≥5% hepatic steatosis and ≥5% hepatic steatosis without inflammation with hepatocyte injury evidence of hepatocellular injury in (eg, ballooning), with or without any the form of hepatocyte ballooning fibrosis Chalasani N, et al. Hepatology. 2017. doi:10.1002/hep.29367 Estimated Global Prevalence of NAFLD: 25% 24% 24% 27% 32% 13% 31% Meta-analysis: NAFLD diagnosed by imaging (US, CT, MRI/SPECT; n=45 studies). Younossi ZM, et al. Hepatology. 2016;64:73-84. 4 Estimated Global NASH Prevalence 6-7% 7-8% 5-6% 8-10% 3-4% 8-9% NASH is Prevalent Globally *25-30% of NAFLD prevalence assumed to be NASH in the above map. 5 Younossi ZM, et al. Hepatology2016;64:73-84; Williams CD, et al. Gasteoenterology 2011;140:124-131. Estimated NASH Prevalence in the U.S. ~30% of U.S. adult population Non-Alcoholic estimated to have NAFLD Fatty Liver Disease NAFLD 83.1 Million Non-Alcoholic Steatohepatitis NASH 16.5 Million Disease Spectrum Disease NASH with 3.3 Million F3/F4 Fibrosis F3 = 2 M; F4 = 1.3 M Unmet Need Estes, et al. Hepatology. 2017. doi:10.1002/hep.29466.
    [Show full text]
  • Lusutrombopag for Treating Thrombocytopenia in People with Chronic Liver Disease Needing a Planned Invasive Procedure
    Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure Technology appraisal guidance Published: 8 January 2020 www.nice.org.uk/guidance/ta617 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights). Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617) Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance are at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian. Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. © NICE 2020. All rights reserved.
    [Show full text]
  • Cricopharyngeal Myotomy Revisited
    10.5005/jp-journals-10023-1019 Sudhakara M Rao et al CASE REPORT Cricopharyngeal Myotomy Revisited 1Sudhakara M Rao, 2Satishchandra T, 2PSN Murthy 1Associate Professor, Department of ENT and Head and Neck Surgery, Dr PSIMS and RF, Gannavaram, Andhra Pradesh, India 2Professor and Head, Department of ENT and Head and Neck Surgery, Dr PSIMS and RF, Gannavaram, Andhra Pradesh, India Correspondence: PSN Murthy, Professor and Head, Department of ENT and Head and Neck Surgery, Dr PSIMS and RF Gannavaram, Andhra Pradesh, India, e-mail: [email protected] ABSTRACT Dysphagia due to neuromuscular in coordination is major disability for the patient. Not able to swallow food or liquids inspite of healthy appetite makes the patient most irritable and can lead to psychological problems. Added to the swallowing problem patient also encounters symptoms and signs of laryngeal penetration or aspiration. For these patients, surgical option of cricopharyngeal myotomy offers a very good relief. We describe two cases where CP myotomy could facilitate a good swallow and prevent laryngeal stimulation or penetration and made a significant improvement in the quality of life of the patients. Keywords: Cricopharyngeal myotomy, Cricopharyngeal spasm, Neurogenic dysphasia, Cricopharyngeus muscle. INTRODUCTION myotomy in the same sitting under GA. He was given nasogastric feeds for 3 days before surgery. During surgery, hypo- Cricopharyngeal spasm can be a primary or secondary to several pharyngoscopy revealed no abnormality of postcricoid area. neurologic disorders.1 Mainly these are the patients who have a Another endotracheal tube was placed in the esophagus to identify basic neurologic disorder from which they were recovering but cricopharyngeal sphincter.
    [Show full text]
  • Management of Flood Syndrome: What Can We Do Better? Strainiene S, Peciulyte M, Strainys T, Stundiene I, Savlan I, Liakina V, Valantinas J
    ISSN 1007-9327 (print) ISSN 2219-2840 (online) World Journal of Gastroenterology World J Gastroenterol 2021 August 28; 27(32): 5297-5459 Published by Baishideng Publishing Group Inc World Journal of W J G Gastroenterology Contents Weekly Volume 27 Number 32 August 28, 2021 OPINION REVIEW 5297 Management of Flood syndrome: What can we do better? Strainiene S, Peciulyte M, Strainys T, Stundiene I, Savlan I, Liakina V, Valantinas J REVIEW 5306 Radiomics and machine learning applications in rectal cancer: Current update and future perspectives Stanzione A, Verde F, Romeo V, Boccadifuoco F, Mainenti PP, Maurea S 5322 Could the burden of pancreatic cancer originate in childhood? Diaconescu S, Gîlcă-Blanariu GE, Poamaneagra S, Marginean O, Paduraru G, Stefanescu G MINIREVIEWS 5341 Application of artificial intelligence in preoperative imaging of hepatocellular carcinoma: Current status and future perspectives Feng B, Ma XH, Wang S, Cai W, Liu XB, Zhao XM 5351 Artificial intelligence application in diagnostic gastrointestinal endoscopy - Deus ex machina? Correia FP, Lourenço LC 5362 Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer Kang YB, Cai Y 5376 Immune checkpoint inhibitor-related hepatotoxicity: A review Remash D, Prince DS, McKenzie C, Strasser SI, Kao S, Liu K ORIGINAL ARTICLE Basic Study 5392 Therapeutic effect of Cistanche deserticola on defecation in senile constipation rat model through stem cell factor/C-kit signaling pathway Zhang X, Zheng FJ, Zhang Z 5404 Recombinant angiopoietin-like
    [Show full text]
  • MBBS Syllabus
    Syllabus BACHELOR OF MEDICINE AND BACHELOR OF SURGERY (MBBS) (4 ½ Years Degree Course + 1 Year Internship) 1/226 NOTICE 1. Amendments made by the Statutory Regulating Council i.e. Medical Council of India in Rules/ Regulations of Graduate Medical Courses shall automatically apply to the Rules/ Regulations of the Mahatma Gandhi University of Medical Sciences & Technology. 2. The University reserves the right to make changes in the syllabus/books/ guidelines, fee– structure or any other information at any time without prior notice. The decision of the University shall be binding on all. 3. The Jurisdiction of all court cases shall be Jaipur Bench of Hon'ble Rajasthan High Court only. 2/226 RULES & REGULATIONS OF BACHELOR OF MEDICINE & BACHELOR OF SURGERY (4½ Years Degree Course + 1 Year Internship) GOALS OF MEDICAL GRADUATE TRAINING PROGRAMME: (1) National Goals: At the end of undergraduate program, the medical student should be able to: (a) Recognize “health for all' as a national goal and right of all citizens and by undergoing training for medical profession, fulfil his/her social obligations towards realization of this goal. (b) Learn various aspects of National policies on health and devote him/her to its practical implementation. (c) Achieve competence in practice of holistic medicine, encompassing promotive, preventive, curative and rehabilitative aspects of common diseases (d) Develop scientific approach, acquire educational experience for proficiency in profession and promote healthy living. (e) Become exemplary citizen by observation
    [Show full text]
  • Nutrition and Blood
    Greater Manchester Joint Formulary Chapter 9: Nutrition and Blood For cost information please go to the most recent cost comparison charts Contents 9.1. Anaemias and some other blood disorders 9.2 Fluids and electrolytes 9.3 Not listed 9.4. Oral nutrition 9.5 Minerals 9.6 Vitamins Key Red drug see GMMMG RAG list Click on the symbols to access this list Amber drug see GMMMG RAG list Click on the symbols to access this list Green drug see GMMMG RAG list Click on the symbols to access this list If a medicine is unlicensed this should be highlighted in the template as follows Drug name Not Recommended OTC Over the Counter In line with NHS England guidance, GM do not routinely support prescribing for conditions which are self-limiting or amenable to self-care. For further details see GM commissioning statement. Order of Drug Choice Where there is no preferred 1st line agent provided, the drug choice appears in alphabetical order. Return to contents Chapter 9 – page 1 of 16 V5.2 Greater Manchester Joint Formulary BNF chapter 9 Nutrition and Blood Section 9.1. Anaemias and some other blood disorders Subsection 9.1.1 Iron-deficiency anaemias Subsection 9.1.1.1 Oral iron First choice Ferrous fumarate 322 mg tabs (100 mg iron) Ferrous fumarate 305 mg caps (100 mg iron) Alternatives Ferrous fumarate 210 mg tabs (68 mg iron) Ferrous sulphate 200 mg tabs (65 mg iron) Ferrous fumarate 140 mg sugar free syrup (45 mg of iron/5 mL) Sodium feredetate 190 mg sugar free elixir (27.5 mg of iron/5 mL) Grey drugs Ferric maltol capsules Items which Criterion 2 (see RAG list) are listed as For treatment of iron deficiency anaemia in patients with Grey are intolerance to, or treatment failure with, two oral iron deemed not supplements.
    [Show full text]
  • Therapeutic Drug Class
    EFFECTIVE Version Department of Vermont Health Access Updated: 10/02/2020 Pharmacy Benefit Management Program /2016 Vermont Preferred Drug List and Drugs Requiring Prior Authorization (includes clinical criteria) The Commissioner for Office of Vermont Health Access shall establish a pharmacy best practices and cost control program designed to reduce the cost of providing prescription drugs, while maintaining high quality in prescription drug therapies. The program shall include: "A preferred list of covered prescription drugs that identifies preferred choices within therapeutic classes for particular diseases and conditions, including generic alternatives" From Act 127 passed in 2002 The following pages contain: • The therapeutic classes of drugs subject to the Preferred Drug List, the drugs within those categories and the criteria required for Prior Authorization (P.A.) of non-preferred drugs in those categories. • The therapeutic classes of drugs which have clinical criteria for Prior Authorization may or may not be subject to a preferred agent. • Within both categories there may be drugs or drug classes that are subject to Quantity Limit Parameters. Therapeutic class criteria are listed alphabetically. Within each category the Preferred Drugs are noted in the left-hand columns. Representative non- preferred agents have been included and are listed in the right-hand column. Any drug not listed as preferred in any of the included categories requires Prior Authorization. Approval of non-preferred brand name products may require trial and failure of at least 2 different generic manufacturers. GHS/Change Healthcare Change Healthcare GHS/Change Healthcare Sr. Account Manager: PRESCRIBER Call Center: PHARMACY Call Center: Michael Ouellette, RPh PA Requests PA Requests Tel: 802-922-9614 Tel: 1-844-679-5363; Fax: 1-844-679-5366 Tel: 1-844-679-5362 Fax: Note: Fax requests are responded to within 24 hrs.
    [Show full text]
  • Promacta® (Eltrombopag)
    Promacta® (eltrombopag) (Oral) Document Number: IC-0099 Last Review Date: 02/04/2020 Date of Origin: 01/01/2012 Dates Reviewed: 12/2012, 03/2013, 02/2014, 09/2014, 06/2015, 09/2015, 01/2016, 01/2017, 01/2018, 12/2018, 01/2019, 02/2020 I. Length of Authorization Coverage is provided for three months and may be renewed. Aplastic Anemia: Use in first-line therapy is limited to a maximum of 6 months of treatment (i.e., may be renewed one time only). Chronic hepatitis C: use is limited to a maximum of 48 weeks of treatment (in combination with interferon) II. Dosing Limits A. Quantity Limit (max daily dose) [Pharmacy Benefit]: 12.5 mg tablets – 1 tablet per day 25 mg tablets – 1 tablet per day 50 mg tablets – 1 tablet per day 75 mg tablets – 2 tablets per day 12.5 mg packet for oral suspension – 1 packet per day 25 mg packet for oral suspension – 3 packets per day B. Max Units (per dose and over time) [Medical Benefit]: 150 mg daily III. Initial Approval Criteria1 Coverage is provided in the following conditions: Universal Criteria Patient is not on any other thrombopoietin receptor agonist or mimetic (e.g., romiplostim, eltrombopag, lusutrombopag, etc.) or fostamtinib; AND Laboratory values are current (i.e., drawn within the previous 28 days); AND Eltrombopag is not being used to attempt to normalize platelet count; AND Proprietary & Confidential © 2020 Magellan Health, Inc. Chronic immune (idiopathic) thrombocytopenia (ITP) †1,2,6,7,8,9,13 Patient aged 1 year or older; AND Patient has had chronic ITP for at least 6 months
    [Show full text]